^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Arenegyr (NGR-hTNF)
i
Other names: NGR-hTNF, CNGRCG peptide-TNF alpha conjugate, CNGRC peptide-TNF alpha conjugate, NGR-TNF, NGR-TNFα, NGRhTNF
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AGC Biologics
Drug class:
Vascular disrupting agent, Capillary permeability modulator, CD13 modulator
Related drugs:
almost3years
Salvage Therapy for Relapsed Malignant Pleural Mesothelioma: A Systematic Review and Network Meta-Analysis. (PubMed, Cancers (Basel))
Patients with malignant pleural mesothelioma (MPM) have very poor prognoses, and pemetrexed plus platinum is the standard first-line therapy...Tremelimumab, vorinostat, nivolumab alone, chemotherapy (CTX), asparagine-glycine-arginine-human tumor necrosis factor plus CTX, and nivolumab plus ipilimumab all produced noticeable PFS benefits compared with placebo. Nivolumab plus ipilimumab had the best PFS ranking (SUCRA: 92.3%). Second-line treatment with nivolumab plus ipilimumab provided the OS and PFS outcomes for patients with relapsed MPM.
Retrospective data • Review • Journal
|
TNFA (Tumor Necrosis Factor-Alpha)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Imjudo (tremelimumab) • pemetrexed • Zolinza (vorinostat) • Arenegyr (NGR-hTNF)
Share via
